Accessibility Menu
Xtant Medical logo

Xtant Medical(NYSEMKT) XTNT

Market Cap$62.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-100%
5 Year-76%
1 Year-46%
1 Month-24%
$0.32
-28.52%
-0.13Today
Xtant Medical last closing stock price
MetricPriceDate
Last closeUSD 0.322026-08-11
Xtant Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-26.57%USD 0.442026-08-04
1 month-23.79%USD 0.422026-07-10
3 month-33.33%USD 0.482026-05-13
Year to date-59.18%USD 0.782025-12-31
1 year-45.51%USD 0.592025-08-11
3 year-72.88%USD 1.182023-08-11
5 year-76.12%USD 1.342021-08-12
Since inception-99.89%USD 420.022010-07-01

Xtant Medical Financials at a Glance

Market Cap

$62.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$109.53M

Net Income (TTM)

-$11.14M

EPS (TTM)

$0.01

P/E Ratio

40.92

Dividend

$0.00

Beta (Volatility)

0.51 (Low)

Price

$0.32

Volume

1,244,951.984

Open

$0.37

Previous Close

$0.32

Daily Range

$0.32 - $0.38

52-Week Range

$0.32 - $0.95

Estimated Earnings Date

Aug 6, 2026

XTNT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xtant Medical

Xtant Medical makes bone grafts and spinal implants for surgeons. Its products help repair bones and support spine surgeries. Hospitals and doctors use these tools to treat injuries and chronic conditions.

Bone Builders and Spine Fixers: What Xtant Sells

  • Orthobiologics (54% of revenue): Bone grafts and tissue products for bone healing, used by orthopedic and neurological surgeons.
  • Spinal Implants (32% of revenue): Metal and plastic devices for spinal fusion and stabilization in back surgeries.
  • License Revenue (14% of revenue): Income from licensing technology and products to other companies, mainly in 2025.
  • Private Label/OEM: Supplies bone grafts and implants for other brands and manufacturers, often at lower margins.
  • Wound Care Products: Amniotic membrane and collagen-based materials for surgical wound management.

Growth Spurts and Strategic Moves

  • Launched new products like nanOss Strata and OsteoVive Plus in 2024–2025.
  • Sold Coflex/CoFix and international hardware business to Companion Spine in December 2025.
  • Expanded U.S. distribution network and national accounts program since 2023.
  • Increased focus on private label and OEM channels for orthobiologics in 2025.
  • Entered new international markets through distribution partners in Europe, Canada, and Latin America.

Why Xtant Stands Out in the Crowd

Xtant offers a wide range of bone and spine products, letting hospitals buy bundled solutions. Its U.S. focus and access to large hospital networks help reach more surgeons. The company holds hundreds of patents and keeps launching new products to stay competitive.

Five Things You Need to Know

  • Revenue was $133.9 million in 2025, up 14% from 2024.
  • Orthobiologics made up 54% of 2025 revenue; spinal implants 32%.
  • Gross profit margin rose to 62.9% in 2025 from 58.2% in 2024.
  • Net income was $5.0 million in 2025, reversing a $16.4 million loss in 2024.
  • U.S. sales were 91% of total revenue in 2025; international sales 9%.

Bottom Line

Xtant has shifted its focus to core bone and spine products, adapting through divestitures and new launches. The company’s broad portfolio and U.S. hospital access support its position in a competitive medical device market.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

151

CEO

Sean E. Browne, MBA

Website

www.xtantmedical.com

Headquarters

Belgrade, MT 59714, US

XTNT Financials

Key Financial Metrics (TTM)

Gross Margin

59.39%

Operating Margin

-9.58%

Net Income Margin

-10.17%

Return on Equity

-23.45%

Return on Capital

9.14%

Return on Assets

-13.98%

Earnings Yield

2.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$62.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

140.26M

Volume

1.24M

Avg. Volume

104.30K

Financials (TTM)

Gross Profit

$65.05M

Operating Income

-$10.50M

EBITDA

-$2.45M

Operating Cash Flow

$570.00K

Capital Expenditure

-$1.27M

Free Cash Flow

-$696.00K

Cash & ST Invst.

$9.87M

Total Debt

$26.01M

Xtant Medical Performance Analysis

Xtant Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 57,969,0004.9%
20232023-12-31USD 91,303,00057.5%
20242024-12-31USD 117,267,00028.4%
20252025-12-31USD 133,927,00014.2%
Xtant Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.1%
Q42025-12-31-2.7%
Q12026-03-31-35.5%
Q22026-06-3010.3%
Xtant Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.0959.1%
20232023-12-31USD 0.01N/A
20242024-12-31USD -0.12N/A
20252025-12-31USD 0.03N/A
Xtant Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-63.2%
Q42025-12-31-95.5%
Q12026-03-31-5225.0%
Q22026-06-30-241.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$23.03M

-35.0%

Gross Profit

$13.33M

-45.1%

Gross Margin

57.88%

N/A

Market Cap

$62.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$414.29K

N/A

Employees

151

N/A

Net Income

-$9.41M

-365.2%

EBITDA

-$8.29M

-238.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.87M

+42.6%

Total Debt

$26.01M

-29.8%

Accounts Receivable

$19.42M

-28.0%

Inventory

$33.29M

-17.1%

Long Term Debt

$9.68M

-60.2%

Short Term Debt

$16.33M

+28.1%

Return on Assets

-13.98%

N/A

Return on Invested Capital

-21.12%

N/A

Free Cash Flow

-$7.56M

-930.2%

Operating Cash Flow

-$7.31M

-672.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXOZeXoZymes, Inc.
$5.76+10.77%
RPIDRapid Micro Biosystems, Inc.
$1.69-1.17%
NSPRInspireMD, Inc.
$0.85+7.10%
ESLAEstrella Immunopharma, Inc.
$0.71-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$97.71+0.00%
SPCXSpace Exploration Technologies
$133.29-0.04%
NVDANvidia
$217.50-0.00%
SMCISuper Micro Computer
$31.60+0.00%

Questions About XTNT

What is the current price of Xtant Medical?

Xtant Medical is trading at $0.32 per share.

What is the 52-week range for Xtant Medical?

Over the past 52 weeks, Xtant Medical has traded between $0.32 and $0.95.

How much debt does Xtant Medical have?

As of the most recent reporting period, Xtant Medical reported total debt of $15.44M.

How much cash does Xtant Medical have on hand?

Xtant Medical reported $12.16M in cash and cash equivalents in its most recent financial results.

What is Xtant Medical’s dividend yield?

Xtant Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services